BioSpace News Archive

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) announced that Larry Jasinski, Chief Executive Officer, will present and host one-on-one meetings with investors virtually at the H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023.

AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, announced results from the company’s REACH-CDM clinical study of the investigational therapy AMO-02 in the treatment of children and adolescents with congenital myotonic dystrophy.

Convergent Therapeutics Inc. today announced the expansion of its leadership team with the appointments of Neil Bander, MD, as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis , MD, as Senior Vice President of Clinical Development.

Redwire Corporation, a leader in space infrastructure for the next generation space economy, announced that Redwire Chairman and Chief Executive Officer Peter Cannito and Chief Financial Officer Jonathan Baliff will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference.

QurAlis today announced it will present preclinical data showing that TDP-43 (TAR DNA-binding protein 43) pathology drives loss of synaptic UNC13A function in neurodegenerative diseases including ALS and frontotemporal dementia (FTD).

Rani Therapeutics Holdings, Inc. today announced that Rani will participate in and present at two upcoming investor conferences in September 2023.

Immuneering Corporation today announced that management will present at the Morgan Stanley Healthcare Conference to discuss the company’s pipeline, platform, and business strategy.

Spero Therapeutics, Inc. today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright Conference.

Acasti Pharma Inc. today announced that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13, 2023 in New York, NY.

PepGen Inc. today announced key highlights from the upcoming presentation of preclinical non-human primate (NHP) data supporting PepGen’s proprietary Enhanced Delivery Oligonucleotide (EDO) platform at the 6th Ottawa International Conference on Neuromuscular Disease and Biology (NMD) being held on September 7-9, 2023.